Printer Friendly

Vitamin D3 lowers inflammatory T cells in multiple sclerosis patients.

Results from a study reported in the journal Neurology suggest a benefit for treatment with high-dose vitamin D for people diagnosed with multiple sclerosis. *

Peter A. Calabresi, MD, and colleagues tested the effects of vitamin D supplementation in a study involving 40 relapsing-remitting multiple sclerosis patients. Participants were treated for six months with 10,400 IU or 800 IU vitamin D. Serum levels of 25-hydroxyvitamin D were measured at the beginning of the study and at three and six months.

Subjects who received the higher dose of vitamin D experienced an average 34.9 ng/mL increase in serum vitamin D by the end of the study, while levels increased by just 6.9 ng/mL in the low-dose group. Among those who received the higher dose, the proportion of pro-inflammatory interleukin 17 (IL-17) producing cells decreased, suggesting a reduction in disease severity.

Editor's Note: "These results are exciting, as vitamin D has the potential to be an inexpensive, safe, and convenient treatment for people with MS," stated Dr. Calabresi, the director of the Johns Hopkins Multiple Sclerosis Center. "We hope that these changes in inflammatory T cell responses translate to a reduced severity of disease. Other clinical trials are underway to determine if that is the case."

* Neurology. 2015 Dec 30.

COPYRIGHT 2016 LE Publications, Inc.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2016 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Title Annotation:IN THE NEWS
Publication:Life Extension
Article Type:Brief article
Date:Jun 1, 2016
Previous Article:Research suggests prenatal carnitine supplementation could help prevent some cases of autism.
Next Article:Meta-analysis adds evidence to antidepressant effect of omega-3.

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters